Search Results

You are looking at 51 - 60 of 196 items for :

  • Refine by Access: All x
Clear All
Full access

Jae Park

chemotherapy, serious toxicities are associated with immune activation. The main toxicity, explained Dr. Park, is cytokine release syndrome (CRS), which manifests similarly to sepsis and is characterized by fever, hypotension, capillary leak, respiratory

Full access

Presenter: Patrick A. Brown

most rapidly within the first week of therapy, which is the high-risk period for CRS,” said Dr. Brown, who noted that CRS is characterized by fever, hypotension, respiratory compromise, and potentially coagulopathy. Neurologic toxicities are the second

Full access

Jimmie C. Holland

), spiritual or religious concerns, and physical problems (eg, breathing problems, constipation, fatigue, fever). Patients can complete the form while in a busy waiting room, and those who have a score of 4 or more (moderate or severe distress) should be

Full access

John A. Thompson

treated) was a much higher incidence of fever. The newest BRAF/MEK inhibitor combination therapy to receive FDA approval is vemurafenib/cobimetinib. The data behind this approval come from the coBRIM clinical trial. 11 , 12 Larkin et al 11 , 12

Full access

John A. Thompson

combination is clearly better than monotherapy,” Dr. Thompson noted. While the combination protects against squamous cell carcinoma, dual blockade can produce fever and chills that often require temporary treatment cessation, with lower doses on resumption of

Full access

John A. Thompson

, peritoneal signs consistent with perforation, ileus, fever), permanently discontinue ipilimumab, evaluate for bowel perforation, consider endoscopy, and give steroids until improvement, then taper over 1 month. Incorporating PD1 Inhibitors

Full access

Daniel C. McFarland, Kelly M. Shaffer, Heather Polizzi, John Mascarenhas, Marina Kremyanskaya, Jimmie Holland, and Ronald Hoffman

with MPNs experience a unique constellation of physical symptoms, such as pruritus, night sweats, bone and splenic pain, fatigue, and fevers. Symptom burden can be similar in severity to the experience of patients with metastatic cancer or acute myeloid

Full access

Maria R. Baer and Ivana Gojo

cytogenetic risk group. Thus, clofarabine shows encouraging results in older patients, including those with unfavorable karyotypes. However, the treatment is myelosuppressive, with most patients requiring hospitalization for neutropenic fever or infection

Full access

Smith Giri, Shadi Hamdeh, Vijaya Raj Bhatt, and James K. Schwarz

experienced disease control for 7 months with the combination of chemotherapy and sorafenib. Case Presentation A 65-year-old man presented to the emergency room who had experienced worsening pain in both calves during the past 2 to 3 weeks, fever and

Full access

Karisa C. Schreck, Andrew Guajardo, Doris D.M. Lin, Charles G. Eberhart, and Stuart A. Grossman

dabrafenib at 150 mg twice daily and trametinib at 2 mg daily, with a Karnofsky performance status (KPS) of 50 and an ECOG performance status (PS) of 3. Treatment was complicated by fevers and a rash that responded to steroids. The steroids were titrated to